Mylan CEO to appear before US congress over EpiPen scandal
September 15, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Hilary Clinton, Mylan, epipen
Following the controversy of Mylan’s price increases to its EpiPen (epinephrine) auto-injector, the company’s CEO Heather Bresch is due to …
GSK’s shingles vaccine tops MSD rival in Ph III testing
September 15, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
GlaxoSmithKline’s shingles vaccine Shingrix has topped rival MSD treatment Zostavax as it is shown to remain effective in elderly patients …
EU approval for Eisai kidney cancer treatment
September 15, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Afinitor, Eisai, Kisplyx, Lenvima, everolimus
The European Commission has approved the use of Eisai’s Kisplyx (lenvatinib) for the treatment of renal cell carcinoma (RCC) following …
Bayer acquires Monsanto in largest-ever deal by a German company
September 14, 2016Business Services, Manufacturing and Production, Sales and Marketing Bayer, acqusition, monsanto
Bayer and Monsanto have signed a definitive merger agreement under which the German drugmaker will acquire the US agricultural group …
Sanofi reveals promising data for FDA-delayed diabetes drug
September 14, 2016Research and Development, Sales and Marketing FDA, Lantus, Sanofi, iglarlixi
Sanofi has announced new Phase III data for its IGlarLixi combination drug for the treatment of diabetes, showing it could …
Bayer raises bid yet again to finalise Monsanto deal
September 14, 2016Manufacturing and Production, Research and Development, Sales and Marketing
Bayer has taken yet another step in its dedicated efforts to acquire Monsanto as it raises its offer to $129 …
Roche’s Ocrevus more effective than Merck’s Rebif, company claims
September 14, 2016Research and Development Merck, Ocrevus, Rebif, Roche, multiple sclerosis
Roche has announced new results from the Phase III studies of investigational medicine Ocrevus (ocrelizumab) studying relapsing multiple sclerosis (RMS) …
Takeda reportedly sets $15bn on US acquisitions
September 14, 2016Manufacturing and Production, Research and Development Takeda, acquisitions
Takeda Pharmaceuticals is reportedly willing to spend as much as $15 billion on acquisitions in the US in efforts to …
Novartis joins $17m funding of chronic inflammatory disease startup
September 14, 2016Research and Development Fountain Healthcare, Novartis, start up financing
Novartis was one of the co-leaders in the $17million series A financing of Irish startup in the development of chronic …
ClinTec appoints Rick Farris as executive vice president of North American Operations
September 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ClinTec, appointment
Clinical research organisation ClinTec has announced the expansion of its US management team with the selection of Rick Farris as …
Eisai reveals new long-term seizure control data at ECE 2016
September 13, 2016Manufacturing and Production, Research and Development Eisai, epilepsy
Eisai has revealed new data on long-term seizure control in different seizure types at the 12th European Congress on Epileptology …
GSK and J&J file rheumatoid arthritis treatment sirukumab in EU
September 13, 2016Manufacturing and Production, Sales and Marketing GSK, GlaxoSmithKline, Johnson & Johnson, rheumatoid arthritis, sarilumab, sirukumab
GlaxoSmithKline and partner Johnson & Johnson’s Janssen Biologics unit have filed for approval of rheumatoid arthritis (RA) treatment sirukumab in …
Proteomics market to grow to $24.8 billion by 2024
September 13, 2016Manufacturing and Production, Research and Development Grand View Research, proteomics
The global proteomics market is predicted to grow to exceed $24.8 billion by 2024, according to a new report by …
Takeda forms “first of its kind” developmental partnership with CRO
September 13, 2016Manufacturing and Production, Research and Development PRA Health Services, Takeda, partnership
Takeda and PRA Health Services have announced a new partnership that will see the Japanese pharma giant transfer 300 staffers …
Horizon buys out Raptor for $800 million
September 13, 2016Manufacturing and Production, Sales and Marketing Horizon Pharma, Raptor Pharmaceutical, acquisition
Irish biopharmaceutical firm Horizon Pharma has finalised an $800 million deal to buy Raptor Pharmaceutical Corp in a bid to …
New Sanofi/Alphabet partnership names CEO
September 12, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alphabet, Sanofi, Verily, appointment, google
As part of the news that French drugmaker Sanofi and Google parent Alphabet’s life sciences firm Verily are to join …
ALS Pharma quadruples Cambridgeshire testing facility in £2m expansion
September 12, 2016Manufacturing and Production, Research and Development, Sales and Marketing ALS Pharmaceutical, Microbiology, expansion
UK microbiology and chemical analysis company ALS Pharmaceutical has quadrupled the size of its facility in Ely, Cambridgeshire as part …
Bayer ponders $1.1 billion portfolio sale to fund Monsanto acquisition
September 12, 2016Business Services, Manufacturing and Production, Sales and Marketing Bayer, acquisition, monsanto
In the latest development in the Bayer-Monsanto saga, the German drugmaker has enlisted the aid of global financial services firm …
GSK sells anaesthetic portfolio to Aspen for up to $372 million
September 12, 2016Sales and Marketing
GlaxoSmithKline is to sell its portfolio of anaesthetic drugs to South African firm Aspen Pharmacare in a deal worth up …
Clinton plan “negative for innovation”, says Pfizer CEO
September 12, 2016Sales and Marketing Hilary Clinton
Democrat presidential candidate Hilary Clinton’s plan to tackle “unjustified price hikes” outlined last week is “very negative for innovation”, according …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
